Adlai Nortye Doses First Patient In The Intermittent Weekly Dosing Arm In Its Ongoing Phase 1 Clinical Trial Of AN9025, A Pan-RAS(ON) Inhibitor

Loading news article.

Adlai Nortye Doses First Patient In The Intermittent Weekly Dosing Arm In Its Ongoing Phase 1 Clinical Trial Of AN9025, A Pan-RAS(ON) Inhibitor | WAPE

Adlai Nortye Doses First Patient In The Intermittent Weekly Dosing Arm In Its Ongoing Phase 1 Clinical Trial Of AN9025, A Pan-RAS(ON) Inhibitor

Article summary

Related companies

Comments —